Bessemer Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $44.7M | Buy |
141,449
+33,590
| +31% | +$7.91M | 0.06% | 213 |
|
|
2026
Q1 | $21.5M | Buy |
107,859
+84,349
| +359% | +$16.7M | 0.03% | 275 |
|
|
2025
Q4 | $4.44M | Buy |
23,510
+22,764
| +3,051% | +$4.37M | 0.01% | 447 |
|
|
2025
Q3 | $132K | Buy |
746
+679
| +1,013% | +$101K | ﹤0.01% | 1220 |
|
|
2025
Q2 | $8K | Buy |
67
+51
| +319% | +$5.45K | ﹤0.01% | 1896 |
|
|
2025
Q1 | $2K | Sell |
16
-22
| -58% | -$2.49K | ﹤0.01% | 2247 |
|
|
2024
Q4 | $4K | Buy |
+38
| New | +$4.3K | ﹤0.01% | 2072 |
|
|
2023
Q3 | – | Sell |
-17
| Closed | -$1K | – | 2255 |
|
|
2023
Q2 | $1K | Buy |
+17
| New | +$1.28K | ﹤0.01% | 2173 |
|
|
2020
Q3 | – | Sell |
-21
| Closed | -$1K | – | 1526 |
|
|
2020
Q2 | $1K | Hold |
21
| – | – | ﹤0.01% | 1670 |
|
|
2020
Q1 | $1K | Sell |
21
-3
| -13% | -$170 | ﹤0.01% | 1580 |
|
|
2019
Q4 | $1K | Buy |
24
+2
| +9% | +$134 | ﹤0.01% | 1593 |
|
|
2019
Q3 | $1K | Buy |
+22
| New | +$1.38K | ﹤0.01% | 1660 |
|
|
2019
Q2 | – | Sell |
-24
| Closed | -$2K | – | 1737 |
|
|
2019
Q1 | $2K | Sell |
24
-10,508
| -100% | -$796K | ﹤0.01% | 1677 |
|
|
2018
Q4 | $891K | Buy |
10,532
+627
| +6% | +$66.8K | ﹤0.01% | 602 |
|
|
2018
Q3 | $1.7M | Buy |
9,905
+287
| +3% | +$43.3K | 0.01% | 453 |
|
|
2018
Q2 | $1.24M | Hold |
9,618
| – | – | ﹤0.01% | 521 |
|
|
2018
Q1 | $991K | Sell |
9,618
-321
| -3% | -$31.7K | ﹤0.01% | 584 |
|
|
2017
Q4 | $849K | Buy |
9,939
+4,135
| +71% | +$358K | ﹤0.01% | 655 |
|
|
2017
Q3 | $493K | Buy |
5,804
+5,770
| +16,971% | +$457K | ﹤0.01% | 853 |
|
|
2017
Q2 | $3K | Hold |
34
| – | – | ﹤0.01% | 1724 |
|
|
2017
Q1 | $2K | Sell |
34
-91
| -73% | -$5.99K | ﹤0.01% | 1680 |
|
|
2016
Q4 | $8K | Sell |
125
-8,759
| -99% | -$553K | ﹤0.01% | 1666 |
|
|
2016
Q3 | $565K | Buy |
8,884
+8,738
| +5,985% | +$642K | ﹤0.01% | 747 |
|
|
2016
Q2 | $11K | Sell |
146
-122
| -46% | -$9.05K | ﹤0.01% | 1070 |
|
|
2016
Q1 | $18K | Sell |
268
-34,828
| -99% | -$2.12M | ﹤0.01% | 1076 |
|
|
2015
Q4 | $2.37M | Hold |
35,096
| – | – | 0.01% | 398 |
|
|
2015
Q3 | $1.88M | Buy |
35,096
+35,019
| +45,479% | +$2.12M | 0.01% | 433 |
|
|
2015
Q2 | $5K | Hold |
77
| – | – | ﹤0.01% | 1359 |
|
|
2015
Q1 | $4K | Buy |
+77
| New | +$2.95K | ﹤0.01% | 1374 |
|
Other funds holding LGND
JT
CAM
Bessemer Group's LGND Position: Q2 2026 in Review
Bessemer Group increased its Ligand Pharmaceuticals (LGND) stake by 31% in Q2 2026, buying an estimated $7.91M and bringing the position to 141,449 shares worth $44.7M. The position accounts for 0.06% of the portfolio, ranked #213.
Bessemer Group first reported a position in LGND in Q1 2015 and has held it in 29 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Bessemer Group held 141,449 shares of Ligand Pharmaceuticals worth $44.7M as of Q2 2026.
- Bessemer Group bought 33,590 Ligand Pharmaceuticals shares in Q2 2026, an estimated $7.91M.
- Ligand Pharmaceuticals made up 0.06% of Bessemer Group's portfolio in Q2 2026, its #213 holding.
- Bessemer Group first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 29 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.